Skip to main content

Articles

Page 27 of 62

  1. The proprotein convertase subtilisin/kexin type 9 (PCSK9) acts via a canonical pathway to regulate circulating low-density lipoprotein-cholesterol (LDL-C) via degradation of the LDL receptor (LDLR) on the live...

    Authors: Ying Tang, Sheng-Lan Li, Jia-Hui Hu, Kai-Jun Sun, Lei-Ling Liu and Dan-Yan Xu
    Citation: Cardiovascular Diabetology 2020 19:33
    Content type: Review Published on:

  2. Biomarkers may contribute to our understanding of the pathophysiology of various diseases. Type 2 diabetes (T2D) and coronary heart disease (CHD) share many clinical and lifestyle risk factors and several biom...

    Authors: Cornelia Huth, Alina Bauer, Astrid Zierer, Julie Sudduth-Klinger, Christa Meisinger, Michael Roden, Annette Peters, Wolfgang Koenig, Christian Herder and Barbara Thorand
    Citation: Cardiovascular Diabetology 2020 19:32
    Content type: Original investigation Published on:

  3. The triglyceride glucose (TyG) index, a simple surrogate estimate of insulin resistance, has been demonstrated to predict cardiovascular (CV) disease morbidity and mortality in the general population and many ...

    Authors: Xiaoteng Ma, Lisha Dong, Qiaoyu Shao, Yujing Cheng, Sai Lv, Yan Sun, Hua Shen, Zhijian Wang, Yujie Zhou and Xiaoli Liu
    Citation: Cardiovascular Diabetology 2020 19:31
    Content type: Original investigation Published on:

  4. Studies specifically examining the association between glycated hemoglobin A1c (HbA1c) levels and ischemic stroke/systemic thromboembolism (IS/SE) risk in atrial fibrillation (AF) patients are limited. Here, w...

    Authors: Yi-Hsin Chan, Chi Chuang, Cze-Ci Chan, Hsin-Fu Lee, Ya-Chi Huang, Yu-Tung Huang, Shang-Hung Chang, Chun-Li Wang, Tze-Fan Chao, Chi-Tai Kuo, Yung-Hsin Yeh and Shih-Ann Chen
    Citation: Cardiovascular Diabetology 2020 19:30
    Content type: Original investigation Published on:

  5. The study regarding load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction is very interesting. But there are a few thing...

    Authors: Bo Liang, Yu-Xiu Zhao and Ning Gu
    Citation: Cardiovascular Diabetology 2020 19:29
    Content type: Commentary Published on:

  6. The Action to Control Cardiovascular Risk in Diabetes (ACCORD)-Lipid study found no evidence of a beneficial effect of statin-fibrate combined treatment, compared to statins alone, on cardiovascular outcomes a...

    Authors: Lin Zhu, Andrew Hayen and Katy J. L. Bell
    Citation: Cardiovascular Diabetology 2020 19:28
    Content type: Original investigation Published on:

  7. High soluble suppression of tumorigenicity-2 (sST2) is a marker of poor prognosis in chronic inflammatory conditions. ST2 and its ligand interleukin (IL)-33 are elevated in adipose tissue of obese individuals....

    Authors: Svitlana Demyanets, Christoph Kaun, Alexandra Kaider, Walter Speidl, Manfred Prager, Stanislav Oravec, Philipp Hohensinner, Johann Wojta and Gersina Rega-Kaun
    Citation: Cardiovascular Diabetology 2020 19:26
    Content type: Original investigation Published on:

  8. The low cost of thiazolidinediones makes them a potentially valuable therapeutic option for the > 300 million economically disadvantaged persons worldwide with type 2 diabetes mellitus. Differential selectivit...

    Authors: Charles E. Leonard, Colleen M. Brensinger, Ghadeer K. Dawwas, Rajat Deo, Warren B. Bilker, Samantha E. Soprano, Neil Dhopeshwarkar, James H. Flory, Zachary T. Bloomgarden, Joshua J. Gagne, Christina L. Aquilante, Stephen E. Kimmel and Sean Hennessy
    Citation: Cardiovascular Diabetology 2020 19:25
    Content type: Original investigation Published on:

  9. Obesity, hypertension and prediabetes contribute greatly to coronary artery disease, heart failure and vascular events, and are the leading cause of mortality and morbidity in developed societies. Salt sensiti...

    Authors: Vijayakumar Sukumaran, Hirotsugu Tsuchimochi, Takashi Sonobe, Mark T. Waddingham, Mikiyasu Shirai and James T. Pearson
    Citation: Cardiovascular Diabetology 2020 19:24
    Content type: Original investigation Published on:

  10. Many studies have reported the predictive value of the atherogenic index of plasma (AIP) in the progression of atherosclerosis and the prognosis of percutaneous coronary intervention (PCI). However, the utilit...

    Authors: Zheng Qin, Kuo Zhou, Yueping Li, Wanjun Cheng, Zhijian Wang, Jianlong Wang, Fei Gao, Lixia Yang, Yingkai Xu, Yafeng Wu, Hua He and Yujie Zhou
    Citation: Cardiovascular Diabetology 2020 19:23
    Content type: Original investigation Published on:

  11. Little is known about whether mitochondria 8-hydroxy-2′-deoxyguanosine (8-OHdG), a biomarker of mitochondrial DNA (mtDNA) oxidative damage, contributes to the development of coronary artery disease (CAD) in di...

    Authors: Xue-bin Wang, Ning-hua Cui, Xia’nan Liu and Xin Liu
    Citation: Cardiovascular Diabetology 2020 19:22
    Content type: Original investigation Published on:

  12. In the secondary prevention of cardiovascular (CV) disease in patients with diabetes, an optimal level of HbA1c, the most widely-used glycemic control indicator, for favorable clinical consequences still remai...

    Authors: Takehiro Funamizu, Hiroshi Iwata, Yuya Nishida, Katsutoshi Miyosawa, Shinichiro Doi, Yuichi Chikata, Jun Shitara, Hirohisa Endo, Hideki Wada, Ryo Naito, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Shinya Okazaki, Kikuo Isoda, Katsumi Miyauchi…
    Citation: Cardiovascular Diabetology 2020 19:21
    Content type: Original investigation Published on:

  13. Empagliflozin (empa), a selective sodium–glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular ...

    Authors: Sin-Hee Park, Muhammad Akmal Farooq, Sébastien Gaertner, Christophe Bruckert, Abdul Wahid Qureshi, Hyun-Ho Lee, Djamel Benrahla, Brigitte Pollet, Dominique Stephan, Patrick Ohlmann, Jean-Marc Lessinger, Eric Mayoux, Cyril Auger, Olivier Morel and Valérie B. Schini-Kerth
    Citation: Cardiovascular Diabetology 2020 19:19
    Content type: Original investigation Published on:

  14. Diabetes mellitus is characterized by chronic vascular inflammation leading to pathological expression of the thrombogenic full length (fl) tissue factor (TF) and its isoform alternatively-spliced (as) TF. Blo...

    Authors: Marco Witkowski, Mario Witkowski, Mona Saffarzadeh, Julian Friebel, Termeh Tabaraie, Loc Ta Bao, Aritra Chakraborty, Andrea Dörner, Bernd Stratmann, Diethelm Tschoepe, Samantha J. Winter, Andreas Krueger, Wolfram Ruf, Ulf Landmesser and Ursula Rauch
    Citation: Cardiovascular Diabetology 2020 19:20
    Content type: Original investigation Published on:

  15. Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better p...

    Authors: Shih-Chieh Shao, Kai-Cheng Chang, Swu-Jane Lin, Rong-Nan Chien, Ming-Jui Hung, Yuk-Ying Chan, Yea-Huei Kao Yang and Edward Chia-Cheng Lai
    Citation: Cardiovascular Diabetology 2020 19:17
    Content type: Original investigation Published on:

  16. Cardiac adipose tissue may have local paracrine effects on epicardial arteries and the underlying myocardium, promoting calcification and affecting myocardial microcirculation. We explored whether the total am...

    Authors: Emilie H. Zobel, Regitse Højgaard Christensen, Signe A. Winther, Philip Hasbak, Christian Stevns Hansen, Bernt J. von Scholten, Lene Holmvang, Andreas Kjaer, Peter Rossing and Tine W. Hansen
    Citation: Cardiovascular Diabetology 2020 19:16
    Content type: Original investigation Published on:

  17. Heart-type fatty acid-binding protein (H-FABP) is a novel marker of myocardial injury and has been reported to be associated with cardiovascular diseases (CVD) including patients with diabetes mellitus (DM). U...

    Authors: Hui-Wen Zhang, Jing-Lu Jin, Ye-Xuan Cao, Hui-Hui Liu, Yan Zhang, Yuan-Lin Guo, Na-Qiong Wu, Ying Gao, Rui-Xia Xu, Qi Hua, Yan-Fang Li, Chuan-Jue Cui, Geng Liu, Qian Dong, Jing Sun and Jian-Jun Li
    Citation: Cardiovascular Diabetology 2020 19:15
    Content type: Original investigation Published on:

  18. Mixed dyslipidemia [elevated non-high-density lipoprotein cholesterol (non-HDL-C) and triglycerides (TGs), and decreased HDL-C] is common in type 2 diabetes mellitus (T2DM) and is associated with increased car...

    Authors: Helen M. Colhoun, Lawrence A. Leiter, Dirk Müller-Wieland, Bertrand Cariou, Kausik K. Ray, Francisco J. Tinahones, Catherine Domenger, Alexia Letierce, Marc Israel, Rita Samuel and Stefano Del Prato
    Citation: Cardiovascular Diabetology 2020 19:14
    Content type: Original investigation Published on:

  19. Sodium–glucose linked cotransporter-2 (SGLT2) inhibitors reduce the likelihood of hospitalization for heart failure and cardiovascular death in both diabetic and non-diabetic individuals with reduced ejection ...

    Authors: Kim A. Connelly, Yanling Zhang, Jean-François Desjardins, Linda Nghiem, Aylin Visram, Sri N. Batchu, Verra G. Yerra, Golam Kabir, Kerri Thai, Andrew Advani and Richard E. Gilbert
    Citation: Cardiovascular Diabetology 2020 19:13
    Content type: Original investigation Published on:

  20. Type 2 diabetes increases the risk of coronary heart disease (CHD), yet the mechanisms involved remain poorly described. Polygenic risk scores (PRS) provide an opportunity to understand risk factors since they...

    Authors: Tianyuan Lu, Vincenzo Forgetta, Oriana H. Y. Yu, Lauren Mokry, Madeline Gregory, George Thanassoulis, Celia M. T. Greenwood and J. Brent Richards
    Citation: Cardiovascular Diabetology 2020 19:12
    Content type: Original investigation Published on:

  21. Insulin resistance may contribute to aortic stiffening that leads to end-organ damage. We examined the cross-sectional association and prospective association of insulin resistance and aortic stiffness in olde...

    Authors: Anna K. Poon, Michelle L. Meyer, Hirofumi Tanaka, Elizabeth Selvin, James Pankow, Donglin Zeng, Laura Loehr, Joshua W. Knowles, Wayne Rosamond and Gerardo Heiss
    Citation: Cardiovascular Diabetology 2020 19:11
    Content type: Original investigation Published on:

  22. Although a variety of antidiabetic drugs have significant protective action on the cardiovascular system, it is still unclear which antidiabetic drugs can improve ventricular remodeling and fundamentally delay...

    Authors: Da-Peng Zhang, Li Xu, Le-Feng Wang, Hong-Jiang Wang and Feng Jiang
    Citation: Cardiovascular Diabetology 2020 19:10
    Content type: Original investigation Published on:

  23. To examine the incidence of atrial fibrillation in individuals with type 2 diabetes compared with age- and sex-matched controls from the general population and its variation in relation to glycaemic control an...

    Authors: Shilan Seyed Ahmadi, Ann-Marie Svensson, Aldina Pivodic, Annika Rosengren and Marcus Lind
    Citation: Cardiovascular Diabetology 2020 19:9
    Content type: Original investigation Published on:

  25. Diabetes mellitus type 2 (DM2) is a risk factor for developing heart failure but there is no specific therapy for diabetic heart disease. Sodium glucose transporter 2 inhibitors (SGLT2I) are recently developed...

    Authors: M. Arow, M. Waldman, D. Yadin, V. Nudelman, A. Shainberg, N. G. Abraham, D. Freimark, R. Kornowski, D. Aravot, E. Hochhauser and M. Arad
    Citation: Cardiovascular Diabetology 2020 19:7
    Content type: Original investigation Published on:

  26. The effect of sodium glucose cotransporter type 2 (SGLT2) inhibitor on left ventricular (LV) longitudinal myocardial function in type 2 diabetes mellitus (T2DM) patients with heart failure (HF) has remained un...

    Authors: Hidekazu Tanaka, Fumitaka Soga, Kazuhiro Tatsumi, Yasuhide Mochizuki, Hiroyuki Sano, Hiromi Toki, Kensuke Matsumoto, Junya Shite, Hideyuki Takaoka, Tomofumi Doi and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2020 19:6
    Content type: Original investigation Published on:

  27. While patients with type 2 diabetes mellitus (T2DM) are at increased risk to develop atrial fibrillation (AF), the mechanistic link between T2DM and AF-susceptibility remains unclear. Common co-morbidities of ...

    Authors: Salva R. Yurista, Herman H. W. Silljé, Michiel Rienstra, Rudolf A. de Boer and B. Daan Westenbrink
    Citation: Cardiovascular Diabetology 2020 19:5
    Content type: Commentary Published on:

  28. This study investigated whether visit-to-visit fasting plasma glucose (FPG) variability, as measured by the coefficient of variation (CV), increased peripheral artery disease (PAD) risk.

    Authors: Chun-Pai Yang, Cheng-Chieh Lin, Chia-Ing Li, Chiu-Shong Liu, Chih-Hsueh Lin, Kai-Lin Hwang, Shing-Yu Yang and Tsai-Chung Li
    Citation: Cardiovascular Diabetology 2020 19:4
    Content type: Original investigation Published on:

  29. Despite increased atherothrombotic risk in type 2 diabetes mellitus, (T2DM) the best preventative antithrombotic strategy remains undetermined. We defined the effects of three antiplatelet agents on functional...

    Authors: William A. E. Parker, Christian Schulte, Temo Barwari, Fladia Phoenix, Sam M. Pearson, Manuel Mayr, Peter J. Grant, Robert F. Storey and Ramzi A. Ajjan
    Citation: Cardiovascular Diabetology 2020 19:3
    Content type: Original investigation Published on:

  30. Peroxisome proliferator-activated receptor-γ (PPAR-γ) modulating treatment may have cardiovascular benefits in type 2 diabetes mellitus (T2DM) patients after ischemic stroke (IS). However, whether there are ad...

    Authors: Chi-Hung Liu, Tsong-Hai Lee, Yu-Sheng Lin, Pi-Shan Sung, Yi-Chia Wei and Yan-Rong Li
    Citation: Cardiovascular Diabetology 2020 19:2
    Content type: Original investigation Published on:

  31. Few prospective studies have compared the cardiovascular benefits of sodium-glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase 4 (DPP-4) inhibitors. We aimed to clarify the efficacy of dapagli...

    Authors: Ayako Fuchigami, Fumika Shigiyama, Toru Kitazawa, Yosuke Okada, Takamasa Ichijo, Mariko Higa, Toru Hiyoshi, Ikuo Inoue, Kaoru Iso, Hidenori Yoshii, Takahisa Hirose and Naoki Kumashiro
    Citation: Cardiovascular Diabetology 2020 19:1
    Content type: Original investigation Published on:

  32. It is unknown that dysglycemia in obese adolescents has effects on myocardial deformation that are more pronounced when compared to obesity alone. We hypothesized that obesity associated abnormal glucose toler...

    Authors: Preneet Cheema Brar, Anne Chun, Xiazhou Fan, Vivek Jani, Mary Craft, Puneet Bhatla and Shelby Kutty
    Citation: Cardiovascular Diabetology 2019 18:172
    Content type: Original investigation Published on:

  33. High-sensitivity troponin I (hs-Tnl) and B-type natriuretic peptide (BNP) are promising prognostic markers for coronary artery disease (CAD). This prospective cohort study investigated whether a combination of...

    Authors: Yuen-Kwun Wong, Chloe Y. Y. Cheung, Clara S. Tang, JoJo S. H. Hai, Chi-Ho Lee, Kui-Kai Lau, Ka-Wing Au, Bernard M. Y. Cheung, Pak-Chung Sham, Aimin Xu, Karen S. L. Lam and Hung-Fat Tse
    Citation: Cardiovascular Diabetology 2019 18:171
    Content type: Original investigation Published on:

  34. Glycemic variation has been suggested to be a risk factor for diabetes-related complications. Previous studies did not address confounding of diabetes duration, number of visits and length of follow-up. Here, ...

    Authors: Roderick C. Slieker, Amber A. W. H. van der Heijden, Giel Nijpels, Petra J. M. Elders, Leen M. ’t Hart and Joline W. J. Beulens
    Citation: Cardiovascular Diabetology 2019 18:170
    Content type: Original investigation Published on:

  35. HbA1c, the most commonly used indicator of chronic glucose metabolism, is closely associated with cardiovascular disease. However, the relationship between HbA1c and the mortality of acute coronary syndrome (A...

    Authors: Wenjun Pan, Haining Lu, Baotao Lian, Pengda Liao, Liheng Guo and Minzhou Zhang
    Citation: Cardiovascular Diabetology 2019 18:169
    Content type: Review Published on:

  36. The use of metformin after acute myocardial infarction (AMI) has been associated with reduced mortality in people with type 2 diabetes mellitus (T2DM). However, it is not known if it is acutely cardioprotectiv...

    Authors: Daniel I. Bromage, Tom R. Godec, Mar Pujades-Rodriguez, Arturo Gonzalez-Izquierdo, S. Denaxas, Harry Hemingway and Derek M. Yellon
    Citation: Cardiovascular Diabetology 2019 18:168
    Content type: Original investigation Published on:

  37. Omentin and adiponectin are among the anti-inflammatory and anti-atherogenic adipokines that have potentially beneficial effects on cardiovascular disorders. Recent studies indicate a paradoxical relationship ...

    Authors: Masami Nishimura, Tomoaki Morioka, Mariko Hayashi, Yoshinori Kakutani, Yuko Yamazaki, Masafumi Kurajoh, Katsuhito Mori, Shinya Fukumoto, Atsushi Shioi, Tetsuo Shoji, Masaaki Inaba and Masanori Emoto
    Citation: Cardiovascular Diabetology 2019 18:167
    Content type: Original investigation Published on:

  38. Type 2 diabetes mellitus (T2DM) is a major cause of heart failure (HF) with preserved ejection fraction (HFpEF), usually presenting as left ventricular (LV) diastolic dysfunction. Thus, LV diastolic function s...

    Authors: Shun Yokota, Hidekazu Tanaka, Yasuhide Mochizuki, Fumitaka Soga, Kentaro Yamashita, Yusuke Tanaka, Ayu Shono, Makiko Suzuki, Keiko Sumimoto, Jun Mukai, Makiko Suto, Hiroki Takada, Kensuke Matsumoto, Yushi Hirota, Wataru Ogawa and Ken-ichi Hirata
    Citation: Cardiovascular Diabetology 2019 18:166
    Content type: Original investigation Published on:

  39. Diabetes mellitus is an important risk factor for atrial fibrillation (AF) development. Sodium–glucose co-transporter-2 (SGLT-2) inhibitors are used for the treatment of type 2 diabetes mellitus (T2DM). Their ...

    Authors: Qingmiao Shao, Lei Meng, Sharen Lee, Gary Tse, Mengqi Gong, Zhiwei Zhang, Jichao Zhao, Yungang Zhao, Guangping Li and Tong Liu
    Citation: Cardiovascular Diabetology 2019 18:165
    Content type: Original investigation Published on:

  40. Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for...

    Authors: Aya Shiraki, Jun-ichi Oyama, Toshiyuki Nishikido and Koichi Node
    Citation: Cardiovascular Diabetology 2019 18:164
    Content type: Original investigation Published on:

  41. Although beta blockers could increase the risk of hypoglycemia, the difference between subtypes on hypoglycemia and mortality have not been studied. This study sought to determine the relationship between type...

    Authors: Kathleen Dungan, Jennifer Merrill, Clarine Long and Philip Binkley
    Citation: Cardiovascular Diabetology 2019 18:163
    Content type: Original investigation Published on:

  42. Statin therapy reduces the risk of cardiovascular events across a broad spectrum of patients; however, it increases the risk of new-onset diabetes (NOD). Although the highest dose pitavastatin is considered to...

    Authors: Han Saem Jeong, Soon Jun Hong, Serhim Son, Hyonggin An, Hyungdon Kook, Hyung Joon Joo, Jae Hyoung Park, Cheol Woong Yu and Do-Sun Lim
    Citation: Cardiovascular Diabetology 2019 18:162
    Content type: Original investigation Published on:

  43. The main aims of this study were to describe trends and outcomes during admission for infective endocarditis (IE) in people ≥ 40 years old with or without type 2 diabetes distributed in five time-periods (2001...

    Authors: José M. de Miguel-Yanes, Rodrigo Jiménez-García, Valentín Hernández-Barrera, Javier de Miguel-Díez, Manuel Méndez-Bailón, Nuria Muñoz-Rivas, Napoleón Pérez-Farinós and Ana López-de-Andrés
    Citation: Cardiovascular Diabetology 2019 18:161
    Content type: Original investigation Published on:

  44. Controversies exist regarding the optimal blood pressure (BP) level that is safe and provides cardiovascular protection in patients with type 2 diabetes mellitus (T2DM) and coexistent coronary artery disease. ...

    Authors: Ying Shen, Yang Dai, Xiao Qun Wang, Rui Yan Zhang, Lin Lu, Feng Hua Ding and Wei Feng Shen
    Citation: Cardiovascular Diabetology 2019 18:160
    Content type: Review Published on:

  45. Microvascular complications (MC) have been claimed to increase the risk for cardiovascular disease in diabetic subjects. However, the effect of MC burden on the risk of major vascular outcomes and all-cause mo...

    Authors: Monia Garofolo, Elisa Gualdani, Rosa Giannarelli, Michele Aragona, Fabrizio Campi, Daniela Lucchesi, Giuseppe Daniele, Roberto Miccoli, Paolo Francesconi, Stefano Del Prato and Giuseppe Penno
    Citation: Cardiovascular Diabetology 2019 18:159
    Content type: Original investigation Published on:

  46. Anagliptin, a dipeptidyl peptidase-4 inhibitor, is reported to reduce the level of low-density lipoprotein cholesterol (LDL-C). The underlying mechanism of this effect and effect on lipid metabolism however re...

    Authors: Atsuko Chihara, Atsushi Tanaka, Takeshi Morimoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Shinichiro Ueda and Koichi Node
    Citation: Cardiovascular Diabetology 2019 18:158
    Content type: Original investigation Published on:

  47. Both type 1 and type 2 diabetes are well-established risk factors for cardiovascular disease and early mortality. However, few studies have directly compared the hazards of cardiovascular outcomes and prematur...

    Authors: You-Bin Lee, Kyungdo Han, Bongsung Kim, Seung-Eun Lee, Ji Eun Jun, Jiyeon Ahn, Gyuri Kim, Sang-Man Jin and Jae Hyeon Kim
    Citation: Cardiovascular Diabetology 2019 18:157
    Content type: Original investigation Published on:

  48. Heart failure (HF) is a common cardiovascular complication of type 2 diabetes (T2D). This secondary analysis investigated baseline factors and treatment differences associated with risk of hospitalization for ...

    Authors: Richard E. Pratley, Mansoor Husain, Ildiko Lingvay, Thomas R. Pieber, Thomas Mark, Hans A. Saevereid, Daniel Vega Møller and Bernard Zinman
    Citation: Cardiovascular Diabetology 2019 18:156
    Content type: Original investigation Published on:

  49. Lower-extremity peripheral artery disease (LE-PAD) and coronary artery disease (CAD) are both pathologically rooted in atherosclerosis, and their shared clinical features regarding the exposure to cardiovascul...

    Authors: Mitsuyoshi Takahara, Osamu Iida, Shun Kohsaka, Yoshimitsu Soga, Masahiko Fujihara, Toshiro Shinke, Tetsuya Amano and Yuji Ikari
    Citation: Cardiovascular Diabetology 2019 18:155
    Content type: Original investigation Published on:

  50. Prediabetes has recently been associated with subclinical atheromatous disease in the middle-aged population. Our aim was to characterize atheromatous plaque burden by the number of affected territories and th...

    Authors: Enric Sánchez, Àngels Betriu, Carolina López-Cano, Marta Hernández, Elvira Fernández, Francisco Purroy, Marcelino Bermúdez-López, Cristina Farràs-Sallés, Silvia Barril, Reinald Pamplona, Ferran Rius, Cristina Hernández, Rafael Simó and Albert Lecube
    Citation: Cardiovascular Diabetology 2019 18:154
    Content type: Original investigation Published on:
journal logo

Cardiovascular Diabetology is affiliated with Sackler Faculty of Medicine, Tel-Aviv University

New Content Item

Submit manuscript

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 8.5
    5-year Journal Impact Factor: 8.9
    Source Normalized Impact per Paper (SNIP): 1.855
    SCImago Journal Rank (SJR): 2.621

    Speed 2023
    Submission to first editorial decision (median days): 2
    Submission to acceptance (median days): 56

    Usage 2023
    Downloads: 2,523,778
    Altmetric mentions: 3,115

Cardiovascular Diabetology

ISSN: 1475-2840